Takeda Pharmaceutical Company （TAK） 2018年20-F年度报告「NYSE」.pdf

1、As filed with the Securities and Exchange Commission on December 17,2018UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 20-F/AAMENDMENT NO.1REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR 12(g)OF THE SECURITIES EXCHANGE ACTOF 1934ORANNUAL REPORT PURSUANT TO SECTION 13 OR 1

2、5(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year endedORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoORSHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934Date of event requir

3、ing this shell company reportCommission file number:Takeda Yakuhin Kogyo Kabushiki Kaisha(Exact name of registrant as specified in its charter)Takeda Pharmaceutical Company Limited(Translation of registrants name into English)Japan1-1,Nihonbashi-Honcho 2-ChomeChuo-ku,Tokyo 103-8668,Japan(Jurisdictio

4、n of incorporation or organization)(Address of principal executive offices)Costa Saroukos1-1,Nihonbashi-Honcho 2-ChomeChuo-ku,Tokyo 103-8668,JapanTel:+81 3 3278-2306Fax:+81 3 3278-2268(Name,Telephone,E-mail and/or Facsimile number and Address of Company Contact Person)Copies to:Keiji Hatano,Esq.,Sul

5、livan&Cromwell LLP,Otemachi First Square,5-1,Otemachi 1-Chome,Chiyoda-ku,Tokyo 100-0004,JapanSecurities registered or to be registered pursuant to Section 12(b)of the Act:Title of Each ClassName of Each Exchange On Which RegisteredAmerican Depositary Shares Representing Common StockCommon Stock,no p

6、ar value*New York Stock Exchange*Listed not for trading,but only in connection with the registration of the American Depositary Shares,pursuant to the requirements of the Securities and Exchange Commission.Securities registered or to be registered pursuant to Section 12(g)of the Act:NoneSecurities f